Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: LPX
News: Latest news
Web Site: Lipoxen
Other Articles: 14-06-201014-06-201026-05-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power

After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Lipoxen

Lipoxen

Lipoxen is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs. 

The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Lipoxen's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.

CLICK HERE FOR FULL ANLAYSIS OF LIPOXEN
Monday, February 08, 2010

Lipoxen granted EU patent for polysialic acid technology StimuXen

company news image

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of differentiated biologicals, vaccines and siRNA delivery, said it has been granted patents for its Polysialylated G-CSF StimuXen proprietary technology in six European territories: the UK, Germany, France, Spain, Italy and Switzerland. The technology aims at protecting the body’s level of white blood cells which is particularly beneficial in chemotherapy patients.

This technology is based on polysialic acid, or PSA, a polymer occurring naturally in humans which extends a protein's active life. PSA is biodegradable, non-immunogenic and non-toxic and is also therefore expected to avoid the toxicity attributed to polyethylene glycol (PEG) in PEGylated protein drug candidates. 

StimuXen uses Lipoxen's patented PolyXen technology to attach polysialic acid onto the N-terminal of G-CSF to produce polysialylated G-CSF.  The patent application related to it is recent and has now been granted in Europe. Preclinical work with StimuXen has shown improved pharmacokinetics and pharmacodynamics which are similar to those of the longest-acting version of G-CSF on the market whose patent expires in 2015, Lipoxen said. G-CSF generated global sales of US$5.2B in 2008.

The G-CSF (granulocyte-colony stimulating factor) stimulates the bone marrow to produce more white blood cells. A major side effect of chemotherapy is a reduction in the number of white blood cells which can lead to a patient's reduced ability to fight infection, consequent to which chemotherapy may be postponed or the dose lowered, neither outcome being optimal for the preferred treatment. Prescription of G-CSF acts to protect the body's level of white blood cells during chemotherapy and is usually administered daily for up to 14 days.

The leading currently available G-CSF therapy is administered once with each cycle of chemotherapy. Lipoxen expects that the improved StimuXen G-CSF will have a similar treatment profile.

CEO M Scott Maguire said: "We are confident that StimuXen, which is currently in pre-clinical development, could be as successful as our two potential billion dollar block-buster products in clinical development, SuliXen, a long acting insulin, and ErepoXen, a long-acting erythropoietin (EPO) both of which are based on this PolyXen technology."

Lipoxen has three proprietary patented technology platforms: PolyXen for extending the efficacy and half life of biologic drugs, ImuXen for creating new vaccines and improving existing vaccines and iRNAblate for the delivery of siRNA, short for small interfering RNA or silencing RNA.

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII.

The company out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen’s commercial agreement partners currently include Baxter, Schering-Plough, the Serum Institute of India Ltd, Genentech, and Genzyme. Furthermore, Baxter, the company's third largest shareholder, and management led the £2.9 million fundraising that the company announced in May 2009.

AddThis Feed Button
Register here to be notified of future Lipoxen articles.

Other Lipoxen articles


Other Lipoxen news

More news ►

Investors interested in Lipoxen recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.